Today: 9 June 2026
AST SpaceMobile stock drops after Blue Origin unveils TeraWave satellite network — what ASTS investors watch next
22 January 2026
1 min read

AST SpaceMobile stock drops after Blue Origin unveils TeraWave satellite network — what ASTS investors watch next

New York, January 21, 2026, 17:35 EST — After-hours

AST SpaceMobile Inc (ASTS.O) shares dropped 7.9% to $103.50 in after-hours on Wednesday, following Blue Origin’s reveal of a massive satellite communications network named TeraWave. The stock traded within a wide range, hitting a low of $96.96 and a high of $120.63 during the session.

This is key now since AST has turned into a go-to for “direct-to-device” satellite service—connecting regular smartphones straight to satellites without needing extra gear. Upcoming constellations, even those years off, could reshape investor views on pricing power and who actually controls the network.

AST remains in build-out mode. The stock tends to react to launch schedules, spectrum moves, and funding news well before any clear revenue figures emerge.

Blue Origin revealed that TeraWave plans to deploy 5,408 optically interconnected satellites spanning low and medium Earth orbit, targeting symmetrical data speeds up to 6 terabits per second. The rollout is slated to begin in the fourth quarter of 2027, with the network aimed at serving data centers, governments, and businesses.

The move would bring another Bezos-backed player into the satellite constellation space, which is largely led by SpaceX’s Starlink. Blue Origin CEO Dave Limp told X, “What makes TeraWave different? It is purpose-built for enterprise customers,” Reuters reported. Reuters

AST, headquartered in Midland, Texas, is rolling out its next-gen “BlueBird” satellites to provide 4G and 5G broadband straight to regular smartphones globally. The firm confirmed that BlueBird 6 took off from India on Dec. 23, with additional launches planned throughout 2025 and 2026. AST SpaceMobile

Founder and CEO Abel Avellan described BlueBird 6 as “a breakthrough moment” in a statement dated Dec. 24, positioning the project as a key step toward large-scale deployment. AST remains on track to launch between 45 and 60 satellites by the end of 2026, with launches scheduled roughly every one to two months. Business Wire

Bank of America took a more measured stance Wednesday, noting that TeraWave “adds to the long list of planned satellite constellations” but doesn’t directly challenge AST’s direct-to-device segment, which it sees as heavily reliant on mobile network operator partnerships. The firm maintained its Neutral rating and kept the price target at $100. TipRanks

The downside remains straightforward: satellites must successfully reach orbit, deploy, and operate as planned, while regulators hold the reins on crucial spectrum and licensing approvals. Legal troubles are mounting too — Pomerantz LLP announced it’s investigating possible claims for AST SpaceMobile investors.

Investors are gearing up for AST’s upcoming quarterly report, eager for details on production speed, launch dates, and funding requirements. According to MarketBeat, the company is expected to release earnings on March 2, after markets close, following its usual schedule.

Stock Market Today

  • S&P 500 Rallies on Chipmaker Gains; Crude Oil Prices Retreat After Iran-Israel Ceasefire Signal
    June 9, 2026, 9:24 AM EDT. The S&P 500 gained +0.30% on Monday, driven by renewed investor interest in artificial intelligence boosting chipmakers. Nasdaq 100 rose +1.58%, while the Dow slipped -0.16%, dragged lower by Apple's -1% drop amid lukewarm AI platform feedback. Crude oil prices surged over +4% initially due to Iran-Israel tensions but retreated after Iran signaled an end to its current military operation. The market discounts a low 3% chance of a +25 basis point rate hike by the Federal Reserve on June 16-17. Treasury yields climbed, with 10-year notes reaching a two-week high of 4.58%, pressured by strong US jobs data and heavy upcoming Treasury auctions. Overseas markets closed mixed, with China's Shanghai Composite down -1.70% and Japan's Nikkei falling -3.85%.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Palantir stock slips after hours as Davos deal headlines stack up; earnings next
Previous Story

Palantir stock slips after hours as Davos deal headlines stack up; earnings next

Applied Materials stock rebounds after tariff scare fades; what to watch next for AMAT
Next Story

Applied Materials stock rebounds after tariff scare fades; what to watch next for AMAT

Go toTop